SYNI
LIVE

Serial Number

79414045

Owner

BIOGENCY PTY LTD

Attorney

Stephen Drysdale

Filing Date

Nov 29, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SYNI Trademark

Serial Number: 79414045 • Registration: 7979910

SYNI is a trademark filed by BIOGENCY PTY LTD on November 29, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

BIOGENCY PTY LTD

8/36 O'Riordan Street

Entity Type: 99

Trademark Details

Filing Date

November 29, 2024

Registration Date

October 14, 2025

Published for Opposition

August 26, 2025

Goods & Services

Food supplements, namely, anti-oxidants; capsules sold empty for pharmaceutical purposes; capsules sold empty for veterinary pharmaceutical preparations; chemical preparations for pharmaceutical use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; collagen based medicated supplements for use as nutritional supplements; decoctions for pharmaceutical purposes to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; antioxidants in the nature of dietary supplements; dietary protein supplements; dietary supplements; dietary supplements for animals; dietary supplements with a cosmetic effect; effervescent pharmaceutical preparations to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; food supplements for medical purposes to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; herbal dietary supplements; dietary nutritional supplements; nutritional supplements; plant extracts, other than essential oils, being dietary supplements; medicated lozenges for pharmaceutical purposes; skin lotions for pharmaceutical purposes; pharmaceutical preparations to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations containing vitamins to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for health care to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for human use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for oral use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for skin care; pharmaceutical preparations for veterinary use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; chemical products in the nature of chemical preparations for pharmaceutical use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; natural pharmaceutical products to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical products to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; tablets being pharmaceuticals to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; food supplements for animals in the nature of vitamins; vitamin supplements; dietary food supplements; nutritional drinks being dietary food supplements; food supplements in the nature of dietary supplements.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 25, 2026 FINO
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 18, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 1, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 31, 2026 OPNR
FINAL DISPOSITION NOTICE SENT TO IB
Apr 24, 2026 FICS
FINAL DISPOSITION PROCESSED
Apr 24, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 14, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 14, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 14, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 26, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 26, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 20, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 18, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 14, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 14, 2025 TROA
REFUSAL PROCESSED BY IB
Jul 5, 2025 RFNT
ASSIGNED TO LIE
Jun 24, 2025 ALIE
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 14, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jun 14, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 11, 2025 RFCR
NON-FINAL ACTION WRITTEN
Apr 10, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 9, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 14, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 14, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 14, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 2, 2025 REPR